Please assess the completion status of the following clinical trial:

Trial Title: Study of Milnacipran Added to Pregabalin for Treatment of Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of fibromyalgia defined by 1990 American College of Rheumatology (ACR) Criteria~* tolerate at least 300 mg/day of pregabalin~* have an incomplete response to pregabalin treatment~Exclusion Criteria:~* suicidal risk~* substance abuse~* pulmonary dysfunction~* renal impairment~* active cardiac disease~* liver disease~* narrow angle glaucoma~* autoimmune disease~* cancer~* inflammatory bowel disease~* unstable endocrine disease~* prostatic enlargement

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Milnacipran Added (Type: EXPERIMENTAL): None
- No Treatment Added (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).